Medicare prescription plan, threat to AWP could impact the ESRD drug market
Neumann, M.E.
Nephrology News and Issues 17(2): 16-17; 21
2003
ISSN/ISBN: 0896-1263 PMID: 12629823 Document Number: 552460
Document emailed within 1 workday
Related Documents
Cundiff, D.K. 2003: Medicare prescription drug benefit realities Medgenmed: Medscape General Medicine 5(4): 28SoRelle, R. 2000: Medicare prescription drug battle heats up Circulation 101(22): E9050-E9051
Rubin, R.J. 2001: The Patients' Bill of Rights and Medicare prescription drug benefits Journal of Medical Practice Management: Mpm 17(2): 59-60
Rudolph, N.V.; Williams, S.S. 2007: Medicare beneficiary knowledge of and experience with prescription drug cards Health Care Financing Review 29(1): 87-101
Mueller, C.; Mueller, K.; Sutton, J. 2004: A rural perspective regarding regulations implementing Titles i and Ii of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) Policy Analysis Brief. W Series 24(6): 1-19
Blackwell, S.A.; Shrank, W.H.; Riley, G.F. 2016: An Assessment of Performance Between Medicare Advantage and Stand-Alone Prescription Drug Plans on two Quality Assurance Measures Journal of Medical Practice Management: Mpm 31(4): 200-208
Gardner, J. 1999: Pharmacists join drug benefit debate. if Medicare offers prescription drug benefit, pharmacists want to be reimbursed Modern Healthcare 29(49): 6
Lucena González, M.I.; Ruiz Ruiz, J.; Andrade Bellido, R.J.; Hidalgo Sánchez, R.; González-Correa, J.A.; García Ruiz, A.; Sánchez de la Cuesta, F. 1995: The impact of hospitalization on drug prescription Medicina Clinica 104(6): 211-215
Agar, J.W.M. 2007: Should the Medicare ESRD program fund daily and nocturnal hemodialysis? Nephrology News and Issues 21(12): 48 51 54 Passim
Iglehart, J.K. 2011: Bundled payment for ESRD--including ESAs in Medicare's dialysis package Minnesota Medicine 94(5): 38-39
Marlow, W.K.; Bartrum, T.E. 2006: Market basket approach to ESRD payment remains elusive despite MedPAC recommendation Nephrology News and Issues 20(7): 12
López de Landache, I.E.; Braceras Izaguirre, L.; Echeto García, A.; Gardeazabal Romillo, M.J.é; Acevedo Heranz, P. 2013: Efficiency in the prescription of drugs. Impact of a health policy: automatic change to prescription by active ingredient Revista de Enfermeria 36(11): 49-52
Laschober, M. 2005: Estimating Medicare advantage lock-in provisions impact on vulnerable Medicare beneficiaries Health Care Financing Review 26(3): 63-79
Price, P.L. 1994: A prescription for a prescription: the treatment for adverse drug reactions South Dakota Journal of Medicine 47(4): 133-134
Mandić, D.; Oresković, S.; Francetić, I. 2001: Oral antibiotic prescription in ambulatory care in 1999--a contribution to the development of methods for drug consumption and prescription surveillance monitoring Collegium Antropologicum 25(2): 459-465
Dayer, P.; Biollaz, Jérôme. 2006: Prescription without authorization to market: in whose interest? Revue Medicale Suisse 2(61): 963-964
Sloane, T. 2007: One hundred percent nonsense. Rule limiting growth of Medicare is a threat to providers, seniors Modern Healthcare 37(18): 20
Fried, I. 1998: Is your organization's market ready for a Medicare PSO? Healthcare Financial Management: Journal of the Healthcare Financial Management Association 52(7): 48-50
Dubman, R. 2013: Gauging the impact of ESRD treatments Nephrology News and Issues 27(9): 12; 14
2002: ESRD data system needs a fix. Lack of updates impacts beneficiaries, costs Medicare; USRDS looks elsewhere for accurate data Nephrology News and Issues 16(5): 8 10